CCAR1 Rabbit Polyclonal Antibody

CCAR1 Rabbit Polyclonal Antibody

To Order : [email protected]

CCAR1 Polyclonal Antibody
ABP58004-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of CCAR1 from Human, Mouse. This CCAR1 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CCAR1 protein at amino acid sequence of 840-920
CCAR1 Polyclonal Antibody
ABP58004-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of CCAR1 from Human, Mouse. This CCAR1 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CCAR1 protein at amino acid sequence of 840-920
CCAR1 Polyclonal Antibody
ABP58004-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of CCAR1 from Human, Mouse. This CCAR1 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CCAR1 protein at amino acid sequence of 840-920
CCAR1 polyclonal antibody
BS8140 50ul
EUR 358
Description: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
CCAR1 Polyclonal Antibody
E-AB-14953-120uL 120uL
EUR 240
Description: Unconjugated
CCAR1 Polyclonal Antibody
E-AB-14953-200uL 200uL
EUR 399
Description: Unconjugated
CCAR1 Polyclonal Antibody
E-AB-14953-20uL 20uL
EUR 73
Description: Unconjugated
CCAR1 Polyclonal Antibody
E-AB-14953-60uL 60uL
EUR 143
Description: Unconjugated
CCAR1 Polyclonal Antibody
BT-AP14733-100ul 100ul Ask for price
Description: May be involved in apoptosis signaling in the presence of the reinoid CD437. Apoptosis induction involves sequestration of 14-3-3 protein(s) and mediated altered expression of multiple cell cycle regulatory genes including MYC, CCNB1 and CDKN1A. Plays a role in cell cycle progression and/or cell proliferation.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,sequence Contaminating sequence. Potential poly-A sequence.,Contains 1 SAP domain.,tissue specificity:Expressed in various epithelial cancer cell lines, including breast, colon, prostate, pancreatic and leukemia. Expression is regulated by growth factors.,
CCAR1 Polyclonal Antibody
BT-AP14733-20ul 20ul Ask for price
Description: May be involved in apoptosis signaling in the presence of the reinoid CD437. Apoptosis induction involves sequestration of 14-3-3 protein(s) and mediated altered expression of multiple cell cycle regulatory genes including MYC, CCNB1 and CDKN1A. Plays a role in cell cycle progression and/or cell proliferation.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,sequence Contaminating sequence. Potential poly-A sequence.,Contains 1 SAP domain.,tissue specificity:Expressed in various epithelial cancer cell lines, including breast, colon, prostate, pancreatic and leukemia. Expression is regulated by growth factors.,
CCAR1 Polyclonal Antibody
BT-AP14733-50ul 50ul Ask for price
Description: May be involved in apoptosis signaling in the presence of the reinoid CD437. Apoptosis induction involves sequestration of 14-3-3 protein(s) and mediated altered expression of multiple cell cycle regulatory genes including MYC, CCNB1 and CDKN1A. Plays a role in cell cycle progression and/or cell proliferation.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,sequence Contaminating sequence. Potential poly-A sequence.,Contains 1 SAP domain.,tissue specificity:Expressed in various epithelial cancer cell lines, including breast, colon, prostate, pancreatic and leukemia. Expression is regulated by growth factors.,
CCAR1 Polyclonal Antibody
E11-201559 100ug/100ul
EUR 225
Description: Available in various conjugation types.
CCAR1 Polyclonal Antibody
JOT-AP14733-100ul 100ul
EUR 220
CCAR1 Polyclonal Antibody
JOT-AP14733-50ul 50ul
EUR 144
CCAR1 Polyclonal Antibody
E44H09166 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody
CCAR1 Polyclonal Antibody
E913595 100ul
EUR 225
Description: Available in various conjugation types.
CCAR1 Polyclonal Antibody
MBS2527945-002mL 0.02mL
EUR 135
CCAR1 Polyclonal Antibody
MBS2527945-006mL 0.06mL
EUR 190
CCAR1 Polyclonal Antibody
MBS2527945-012mL 0.12mL
EUR 265
CCAR1 Polyclonal Antibody
MBS2527945-02mL 0.2mL
EUR 415
CCAR1 Polyclonal Antibody
MBS2527945-5x02mL 5x0.2mL
EUR 1835
CCAR1 Polyclonal Antibody
MBS9133629-002mL 0.02mL
EUR 200
CCAR1 Polyclonal Antibody
MBS9133629-005mL 0.05mL
EUR 255
CCAR1 Polyclonal Antibody
MBS9133629-01mL 0.1mL
EUR 345
CCAR1 Polyclonal Antibody
MBS9133629-02mL 0.2mL
EUR 545
CCAR1 Polyclonal Antibody
MBS9133629-5x02mL 5x0.2mL
EUR 2265
CCAR1 Polyclonal Antibody
MBS9125391-002mL 0.02mL
EUR 200
CCAR1 Polyclonal Antibody
MBS9125391-005mL 0.05mL
EUR 255
CCAR1 Polyclonal Antibody
MBS9125391-01mL 0.1mL
EUR 345
CCAR1 Polyclonal Antibody
MBS9125391-02mL 0.2mL
EUR 545
CCAR1 Polyclonal Antibody
MBS9125391-5x02mL 5x0.2mL
EUR 2265
CCAR1 Polyclonal Antibody
MBS8568311-01mL 0.1mL
EUR 305
CCAR1 Polyclonal Antibody
MBS8568311-01mLAF405L 0.1mL(AF405L)
EUR 565
CCAR1 Polyclonal Antibody
MBS8568311-01mLAF405S 0.1mL(AF405S)
EUR 565
CCAR1 Polyclonal Antibody
MBS8568311-01mLAF610 0.1mL(AF610)
EUR 565
CCAR1 Polyclonal Antibody
MBS8568311-01mLAF635 0.1mL(AF635)
EUR 565
CCAR1 Polyclonal Antibody
MBS8530913-01mg 0.1mg
EUR 305
CCAR1 Polyclonal Antibody
MBS8530913-01mLAF405L 0.1mL(AF405L)
EUR 465
CCAR1 Polyclonal Antibody
MBS8530913-01mLAF405S 0.1mL(AF405S)
EUR 465
CCAR1 Polyclonal Antibody
MBS8530913-01mLAF610 0.1mL(AF610)
EUR 465
CCAR1 Polyclonal Antibody
MBS8530913-01mLAF635 0.1mL(AF635)
EUR 465
CCAR1 Polyclonal Antibody
RD78024A-120uL 120μL
EUR 360
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE.
CCAR1 Polyclonal Antibody
RD78024A-200uL 200μL
EUR 630
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE.
CCAR1 Polyclonal Antibody
RD78024A-20uL 20μL
EUR 109.5
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE.
CCAR1 Polyclonal Antibody
RD78024A-60uL 60μL
EUR 214.5
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE.
CCAR1 Polyclonal Antibody
UB-GEN-6292 100 ul
EUR 200
CCAR2 Rabbit Polyclonal Antibody
E10G13710 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody
CCAR2 Rabbit Polyclonal Antibody
E10G06826 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1)
MBS1491743-005mL 0.05mL
EUR 190
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1)
MBS1491743-01mL 0.1mL
EUR 270
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1)
MBS1491743-5x01mL 5x0.1mL
EUR 1205
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1)
MBS1499980-005mL 0.05mL
EUR 190
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1)
MBS1499980-01mL 0.1mL
EUR 270
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1)
MBS1499980-5x01mL 5x0.1mL
EUR 1205
KIAA1967 (CCAR2) rabbit polyclonal antibody, Aff - Purified
AP20449PU-N 100 µg Ask for price
Rabbit Polyclonal Anti-CCAR1 Antibody
TA349891 100 µl Ask for price
Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA)
IRBAMLCCAR1AP953120UL each
EUR 259
Description: Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA)
Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA)
IRBAMLCCAR1AP953200UL each
EUR 403
Description: Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA)
Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4)(IHC, ELISA)
MBS8423047-INQUIRE INQUIRE Ask for price
CCAR1 Rabbit pAb
A13595 100μL
EUR 623.48
CCAR1 Rabbit pAb
A13595-100ul 100 ul
EUR 369.6
CCAR1 Rabbit pAb
A13595-200ul 200 ul
EUR 550.8
CCAR1 Rabbit pAb
A13595-20ul 20 ul
EUR 219.6
CCAR1 Rabbit pAb
A13595-50ul 50 ul
EUR 267.6
CCAR1 Rabbit pAb
A6334 100μL
EUR 1246.96
CCAR1 Rabbit pAb
A6334-100ul 100 ul
EUR 369.6
CCAR1 Rabbit pAb
A6334-200ul 200 ul
EUR 550.8
CCAR1 Rabbit pAb
A6334-20ul 20 ul
EUR 219.6
CCAR1 Rabbit pAb
A6334-50ul 50 ul
EUR 267.6
CCAR1 Rabbit pAb
E2506334 100ul
EUR 225
Description: Available in various conjugation types.
CCAR1 Rabbit pAb
E2513595 100ul
EUR 225
Description: Available in various conjugation types.
CCAR1 Rabbit pAb
E2122236 100ul
EUR 225
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody
CCAR1 Rabbit pAb
E45R30199N 50 ul
EUR 297.75
CCAR1 Rabbit pAb
E45R20175N 50 ul
EUR 297.75
CCAR1 Rabbit pAb
MBS8546027-01mL 0.1mL
EUR 305
CCAR1 Rabbit pAb
MBS8546027-01mLAF405L 0.1mL(AF405L)
EUR 565
CCAR1 Rabbit pAb
MBS8546027-01mLAF405S 0.1mL(AF405S)
EUR 565
CCAR1 Rabbit pAb
MBS8546027-01mLAF610 0.1mL(AF610)
EUR 565
CCAR1 Rabbit pAb
MBS8546027-01mLAF635 0.1mL(AF635)
EUR 565
CCAR1 Rabbit pAb
MBS8549123-01mL 0.1mL
EUR 305
CCAR1 Rabbit pAb
MBS8549123-01mLAF405L 0.1mL(AF405L)
EUR 565
CCAR1 Rabbit pAb
MBS8549123-01mLAF405S 0.1mL(AF405S)
EUR 565
CCAR1 Rabbit pAb
MBS8549123-01mLAF610 0.1mL(AF610)
EUR 565
CCAR1 Rabbit pAb
MBS8549123-01mLAF635 0.1mL(AF635)
EUR 565
Anti-CCAR1 Antibody, Rabbit Polyclonal
MBS8119180-01mL 0.1mL
EUR 300
Anti-CCAR1 Antibody, Rabbit Polyclonal
MBS8119180-5x01mL 5x0.1mL
EUR 1200
Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence)
IRBAHUCCAR1AP738120UL each
EUR 247
Description: Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence)
Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence)
IRBAHUCCAR1AP738200UL each
EUR 383
Description: Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence)
CCAR1 antibody
38833-100ul 100ul
EUR 302.4
CCAR1 Antibody
36417 100ul
EUR 319
CCAR1 Antibody
36417-100ul 100ul
EUR 302.4
CCAR1 Antibody
ABD2281 100 ug
EUR 525.6
CCAR1 Antibody
DF2281 200ul
EUR 420
CCAR1 Antibody
DF2281-100ul 100ul
EUR 168
Description: WB,ELISA(peptide)
CCAR1 Antibody
DF2281-200ul 200ul
EUR 210
Description: WB,ELISA(peptide)
CCAR1 Antibody
1-CSB-PA816898ESR1HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against CCAR1. Recognizes CCAR1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200
CCAR1 Antibody
1-CSB-PA816898ESR2HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against CCAR1. Recognizes CCAR1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:2000
CCAR1 Antibody
1-CSB-PA138742
  • Ask for price
  • Ask for price
  • 50ul
  • 100ul
Description: A polyclonal antibody against CCAR1. Recognizes CCAR1 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200
CCAR1 Antibody
C42925-100ul 100μl
EUR 217
Description: CCAR1 Rabbit Polyclonal Antibody
CCAR1 Antibody
C42925-50ul 50μl
EUR 143.5
Description: CCAR1 Rabbit Polyclonal Antibody
CCAR1 Antibody
GWB-Q00660 0.1 mg Ask for price
CCAR1 Antibody
E036417 100μg/100μl
EUR 255
Description: Available in various conjugation types.
CCAR1 Antibody
E309912 200ul
EUR 275
Description: Available in various conjugation types.
CCAR1 Antibody
E96334 100ul
EUR 255
Description: Available in various conjugation types.
CCAR1 Antibody
MBS5400357-01mg 0.1mg
EUR 445
CCAR1 Antibody
MBS5400357-5x01mg 5x0.1mg
EUR 1855
CCAR1 Antibody
MBS7125462-005mL 0.05mL
EUR 190
CCAR1 Antibody
MBS7125462-01mL 0.1mL
EUR 270
CCAR1 Antibody
MBS7125462-5x01mL 5x0.1mL
EUR 1205
CCAR1 Antibody
MBS9603815-01mL 0.1mL
EUR 260
CCAR1 Antibody
MBS9603815-02mL 0.2mL
EUR 305
CCAR1 Antibody
MBS9603815-5x02mL 5x0.2mL
EUR 1220
CCAR1 Antibody
MBS9412823-01mL 0.1mL
EUR 305
CCAR1 Antibody
MBS9412823-5x01mL 5x0.1mL
EUR 1230
CCAR2 Polyclonal Antibody
30832 100ul
EUR 439
CCAR2 Polyclonal Antibody
30832-100ul 100ul
EUR 302.4
CCAR2 Polyclonal Antibody
30832-50ul 50ul
EUR 224.4
CCAR2 polyclonal antibody
BS8727 50 ul
EUR 358
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
CCAR2 Polyclonal Antibody
E-AB-61542-120uL 120uL
EUR 320
Description: Unconjugated
CCAR2 Polyclonal Antibody
E-AB-61542-200uL 200uL
EUR 530
Description: Unconjugated
CCAR2 Polyclonal Antibody
E-AB-61542-60uL 60uL
EUR 200
Description: Unconjugated
CCAR2 Polyclonal Antibody
E-AB-61542-each each Ask for price
Description: Unconjugated
CCAR2 Polyclonal Antibody
E-AB-52105-120uL 120uL
EUR 240
Description: Unconjugated
CCAR2 Polyclonal Antibody
E-AB-52105-200uL 200uL
EUR 399
Description: Unconjugated
CCAR2 Polyclonal Antibody
E-AB-52105-20uL 20uL
EUR 73
Description: Unconjugated
CCAR2 Polyclonal Antibody
E-AB-52105-60uL 60uL
EUR 143
Description: Unconjugated
CCAR2 Polyclonal Antibody
MBS2562007-002mL 0.02mL
EUR 135
CCAR2 Polyclonal Antibody
MBS2562007-006mL 0.06mL
EUR 190
CCAR2 Polyclonal Antibody
MBS2562007-012mL 0.12mL
EUR 265
CCAR2 Polyclonal Antibody
MBS2562007-02mL 0.2mL
EUR 415
CCAR2 Polyclonal Antibody
MBS2562007-5x02mL 5x0.2mL
EUR 1835
CCAR2 Polyclonal Antibody
MBS2535168-006mL 0.06mL
EUR 190
CCAR2 Polyclonal Antibody
MBS2535168-012mL 0.12mL
EUR 265
CCAR2 Polyclonal Antibody
MBS2535168-02mL 0.2mL
EUR 415
CCAR2 Polyclonal Antibody
MBS2535168-5x02mL 5x0.2mL
EUR 1835
CCAR2 Polyclonal Antibody
MBS9125196-002mL 0.02mL
EUR 200
CCAR2 Polyclonal Antibody
MBS9125196-005mL 0.05mL
EUR 255
CCAR2 Polyclonal Antibody
MBS9125196-01mL 0.1mL
EUR 345
CCAR2 Polyclonal Antibody
MBS9125196-02mL 0.2mL
EUR 545
CCAR2 Polyclonal Antibody
MBS9125196-5x02mL 5x0.2mL
EUR 2265
CCAR2 Polyclonal Antibody
MBS9433963-005mL 0.05mL
EUR 300
CCAR2 Polyclonal Antibody
MBS9433963-01mL 0.1mL
EUR 390
CCAR2 Polyclonal Antibody
MBS9433963-5x01mL 5x0.1mL
EUR 1610
CCAR2 Polyclonal Antibody
RD84308A-120uL 120μL
EUR 360
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).
CCAR2 Polyclonal Antibody
RD84308A-200uL 200μL
EUR 630
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).
CCAR2 Polyclonal Antibody
RD84308A-60uL 60μL
EUR 204
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).
CCAR2 Polyclonal Antibody
RD252105A-120uL 120μL
EUR 360
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).
CCAR2 Polyclonal Antibody
RD252105A-200uL 200μL
EUR 630
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).
CCAR2 Polyclonal Antibody
RD252105A-20uL 20μL
EUR 109.5
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).
CCAR2 Polyclonal Antibody
RD252105A-60uL 60μL
EUR 214.5
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).
CCAR1 Antibody FITC
MBS5400359-01mg 0.1mg
EUR 560
CCAR1 Antibody FITC
MBS5400359-5x01mg 5x0.1mg
EUR 2380
CCAR1 Antibody BIOTIN
MBS5400358-01mg 0.1mg
EUR 560
CCAR1 Antibody BIOTIN
MBS5400358-5x01mg 5x0.1mg
EUR 2380
CCAR1 Conjugated Antibody
C36417 100ul
EUR 476.4
CCAR1 Conjugated Antibody
MBS9446876-01mLAF350 0.1mL(AF350)
EUR 480
CCAR1 Conjugated Antibody
MBS9446876-01mLAF405 0.1mL(AF405)
EUR 480
CCAR1 Conjugated Antibody
MBS9446876-01mLAF488 0.1mL(AF488)
EUR 480
CCAR1 Conjugated Antibody
MBS9446876-01mLAF555 0.1mL(AF555)
EUR 480
CCAR1 Conjugated Antibody
MBS9446876-01mLBiotin 0.1mL(Biotin)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
C31969 100ul
EUR 476.4
CCAR2 Polyclonal Conjugated Antibody
C30832 100ul
EUR 476.4
CCAR2 Polyclonal Conjugated Antibody
MBS9442008-01mLAF350 0.1mL(AF350)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9442008-01mLAF405 0.1mL(AF405)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9442008-01mLAF488 0.1mL(AF488)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9442008-01mLAF555 0.1mL(AF555)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9442008-01mLBiotin 0.1mL(Biotin)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9443142-01mLAF350 0.1mL(AF350)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9443142-01mLAF405 0.1mL(AF405)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9443142-01mLAF488 0.1mL(AF488)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9443142-01mLAF555 0.1mL(AF555)
EUR 480
CCAR2 Polyclonal Conjugated Antibody
MBS9443142-01mLBiotin 0.1mL(Biotin)
EUR 480
Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA)
IRBAMLCCAR2AAP105120UL each
EUR 259
Description: Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA)
Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA)
IRBAMLCCAR2AAP105200UL each
EUR 403
Description: Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA)
Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4)(IHC, ELISA)
MBS8423048-INQUIRE INQUIRE Ask for price
CCAR1 Antibody - middle region
MBS3221149-01mL 0.1mL
EUR 455
CCAR1 Antibody - middle region
MBS3221149-5x01mL 5x0.1mL
EUR 1995
OACA07815-50UL - CCAR1 Antibody
OACA07815-50UL 50ul
EUR 189
OACA06958-50UL - CCAR1 Antibody
OACA06958-50UL 50ul
EUR 189
OACA07815-100UL - CCAR1 Antibody
OACA07815-100UL 100ul
EUR 230
OACA06958-100UL - CCAR1 Antibody
OACA06958-100UL 100ul
EUR 230
C144A Rabbit Polyclonal Antibody
BT-AP06670-100ul 100ul Ask for price
C144A Rabbit Polyclonal Antibody
BT-AP06670-20ul 20ul Ask for price
C144A Rabbit Polyclonal Antibody
BT-AP06670-50ul 50ul Ask for price
C163A Rabbit Polyclonal Antibody
BT-AP00915-100ul 100ul Ask for price
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.|
C163A Rabbit Polyclonal Antibody
BT-AP00915-20ul 20ul Ask for price
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.|
C163A Rabbit Polyclonal Antibody
BT-AP00915-50ul 50ul Ask for price
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.|
C163A Rabbit Polyclonal Antibody
BT-AP00916-100ul 100ul Ask for price
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.|
C163A Rabbit Polyclonal Antibody
BT-AP00916-20ul 20ul Ask for price
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.|
C163A Rabbit Polyclonal Antibody
BT-AP00916-50ul 50ul Ask for price
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.|
C2C4A Rabbit Polyclonal Antibody
BT-AP00934-100ul 100ul Ask for price
C2C4A Rabbit Polyclonal Antibody
BT-AP00934-20ul 20ul Ask for price
C2C4A Rabbit Polyclonal Antibody
BT-AP00934-50ul 50ul Ask for price
CC74A Rabbit Polyclonal Antibody
BT-AP07265-100ul 100ul Ask for price
CC74A Rabbit Polyclonal Antibody
BT-AP07265-20ul 20ul Ask for price
CC74A Rabbit Polyclonal Antibody
BT-AP07265-50ul 50ul Ask for price
C163A Rabbit Polyclonal Antibody
JOT-AP00915-100ul 100ul
EUR 220
C163A Rabbit Polyclonal Antibody
JOT-AP00915-50ul 50ul
EUR 144
C163A Rabbit Polyclonal Antibody
JOT-AP00916-100ul 100ul
EUR 220
C163A Rabbit Polyclonal Antibody
JOT-AP00916-50ul 50ul
EUR 144
C2C4A Rabbit Polyclonal Antibody
JOT-AP00934-100ul 100ul
EUR 220
C2C4A Rabbit Polyclonal Antibody
JOT-AP00934-50ul 50ul
EUR 144
C144A Rabbit Polyclonal Antibody
JOT-AP06670-100ul 100ul
EUR 220
C144A Rabbit Polyclonal Antibody
JOT-AP06670-50ul 50ul
EUR 144
CC74A Rabbit Polyclonal Antibody
JOT-AP07265-100ul 100ul
EUR 220
CC74A Rabbit Polyclonal Antibody
JOT-AP07265-50ul 50ul
EUR 144
CC50A Rabbit Polyclonal Antibody
ES10504-100ul 100ul
EUR 124
Description: WB, ELISA
CC50A Rabbit Polyclonal Antibody
ES10504-50ul 50ul
EUR 74
Description: WB, ELISA

CCAR1 Rabbit Polyclonal Antibody